ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,351.89
-0.77%
Dow Jones
39,872.99
0.00%
Gold vs US Dollar
2,411.645
-0.40%
Brent Oil
81.875
-0.69%
Bitcoin
69,600.01
-0.76%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ambrx Biopharma Inc (AMAM)

  7. Ambrx Biopharma Inc (AMAM) News

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMAM
DateTimeSourceHeadlineSymbolCompany
18/03/202418:45Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:AMAMAmbrx Biopharma Inc
12/03/202420:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
11/03/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202418:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202418:34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202418:29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202418:24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202418:20Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
07/03/202418:23Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AMAMAmbrx Biopharma Inc
07/03/202413:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
06/03/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
23/02/202419:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMAMAmbrx Biopharma Inc
22/02/202413:31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMAMAmbrx Biopharma Inc
22/02/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
12/02/202418:43PR Newswire (US)Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
10/01/202420:07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202419:54Dow Jones NewsTrending: Johnson & Johnson and Merck & Co. Announce AcquisitionsNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202415:04Dow Jones NewsAmbrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & JohnsonNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202413:12Dow Jones NewsJohnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 BillionNASDAQ:AMAMAmbrx Biopharma Inc
23/10/202322:19Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:AMAMAmbrx Biopharma Inc
15/09/202321:27Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:AMAMAmbrx Biopharma Inc
15/09/202321:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
06/09/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
25/08/202322:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
19/07/202314:49Dow Jones NewsAmbrx Biopharma Gets Fast Track Designation for ARX517 Cancer TreatmentNASDAQ:AMAMAmbrx Biopharma Inc
28/06/202321:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202321:45Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202321:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202321:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
09/06/202321:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMAMAmbrx Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:AMAM

Your Recent History

TSXV
NAR
North Arrow Minerals
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved